Kashiv BioSciences signs an exclusive licensing and supply agreement with Intas Pharmaceuticals to commercialize a complex peptide product in Europe, the UK, and India.
Read MoreBinish Chudgar
Prothya Biosolutions Acquisition Marks Intas’s Global Expansion in Plasma-Derived Medicines
Prothya Biosolutions operates plasma collection centres across Hungary and employs approximately 1200 people, making it one of Europe’s largest plasma fractionators.
Read More
UDENYCA Acquired by Intas Pharmaceuticals and Accord BioPharma in Biosimilar Expansion
UDENYCA, a biosimilar to Amgen’s Neulasta, is indicated to reduce the risk of infection due to febrile neutropenia in patients with non-myeloid malignancies undergoing myelosuppressive chemotherapy.
Read More